2025
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer
Herbst R, John T, Grohé C, Goldman J, Kato T, Laktionov K, Bonanno L, Tiseo M, Majem M, Dómine M, Ahn M, Kowalski D, Pérol M, Sriuranpong V, Özgüroğlu M, Bhetariya P, Markovets A, Rukazenkov Y, Muldoon C, Robichaux J, Hartmaier R, Tsuboi M, Wu Y. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer. Nature Medicine 2025, 31: 1958-1968. PMID: 40097663, PMCID: PMC12176615, DOI: 10.1038/s41591-025-03577-y.Peer-Reviewed Original ResearchConceptsMolecular residual diseaseDisease-free survivalNon-small-cell lung cancerDisease-free survival eventsEvent-free rateAdjuvant osimertinibOsimertinib treatmentStage IB-IIIA non-small-cell lung cancerLung cancerOverall survival improvementEvent-free statusPosttreatment Follow-upExploratory post hoc analysisYear adjuvant treatmentPost Hoc AnalysisDFS eventsOsimertinib groupResidual diseaseTreatment discontinuationPlacebo groupAdjuvant therapyAdjuvant treatmentSurvival improvementOsimertinibFollow-up
2024
A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19
Seethamraju H, Yang O, Loftus R, Ogbuagu O, Sammartino D, Mansour A, Sacha J, Ojha S, Hansen S, Arman A, Lalezari J. A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19. Clinical Therapeutics 2024, 46: 891-899. PMID: 39353749, DOI: 10.1016/j.clinthera.2024.08.019.Peer-Reviewed Original ResearchMild to moderate COVID-19National Early Warning Score 2SARS-CoV-2 infectionPost Hoc AnalysisSARS-CoV-2Randomized placebo-controlled trialHoc AnalysisHuman IgG4 monoclonal antibodyModerate-to-severe diseaseViral replicationHIV-1 infectionPlacebo-controlled studyProduction of pro-inflammatory cytokinesExcessive production of pro-inflammatory cytokinesMild-to-moderateAdverse event ratesExploratory post hoc analysisTotal symptom scorePathophysiology of SARS-CoV-2 infectionPro-inflammatory cytokinesHeightened immune responsePathophysiology of COVID-19IgG4 monoclonal antibodyPlacebo groupDouble-blindSuicide-Specific Cognitions and Suicidal Behavior in U.S. Military Veterans
Fischer I, Nichter B, Trachik B, Bryan C, Pietrzak R. Suicide-Specific Cognitions and Suicidal Behavior in U.S. Military Veterans. Psychiatry 2024, 87: 241-250. PMID: 38832675, DOI: 10.1080/00332747.2024.2352883.Peer-Reviewed Original ResearchSuicide-specific cognitionsU.S. military veteransMilitary veteransSuicidal ideationSuicide planLifetime history of suicide attemptsHistory of suicide attemptsAssociated with suicidal ideationSuicide Cognitions ScaleDepressive symptom severityThoughts of suicideMitigate suicide riskB-SCSAdverse childhood experiencesExploratory post hoc analysisSuicidal behaviorLifetime historySuicide riskSuicide attemptsSymptom severitySuicidal thoughtsCognitive scalesIndicator of riskChildhood experiencesIntervention efforts
2023
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
Al-Sawaf O, Zhang C, Jin H, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang Y, Fink A, Tausch E, Schneider C, Ritgen M, Kreuzer K, Chyla B, Paulson J, Pallasch C, Frenzel L, Peifer M, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nature Communications 2023, 14: 2147. PMID: 37072421, PMCID: PMC10113251, DOI: 10.1038/s41467-023-37648-w.Peer-Reviewed Original ResearchConceptsProgression-free survivalChronic lymphocytic leukemiaUntreated chronic lymphocytic leukemiaLymphocytic leukemiaAssociated with longer progression-free survivalParallel-group phase 3 studyProgression-free survival ratesTreatment of chronic lymphocytic leukemiaLonger progression-free survivalDepth of remissionMedian Follow-UpPhase 3 studyAssociated with increased expressionLong-term efficacyLong-term outcomesExploratory post hoc analysisPost Hoc AnalysisMRD statusBCL2 inhibitionOverall survivalPrimary endpointSecondary endpointsInflammatory response pathwaysVenetoclax-obinutuzumabFollow-up
2016
Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial
Veenstra-VanderWeele J, Cook E, King B, Zarevics P, Cherubini M, Walton-Bowen K, Bear M, Wang P, Carpenter R. Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial. Neuropsychopharmacology 2016, 42: 1390-1398. PMID: 27748740, PMCID: PMC5436109, DOI: 10.1038/npp.2016.237.Peer-Reviewed Original ResearchConceptsAutism spectrum disorderFragile X syndromeSpectrum disorderClinician-rated Clinical Global ImpressionAnimal models of fragile X syndromeGABA-BModel of fragile X syndromeSocial avoidance symptomsClinical Global ImpressionPlacebo-ControlledGABA-B agonistSubgroups of individualsPilot open-label trialExploratory post hoc analysisAffective labilityAvoidance symptomsPost hoc analysis of participantsOpen-label trialBehavioral phenotypesGlobal ImpressionArbaclofenSecondary analysisX syndromeSocial behaviorSocial domains
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply